Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
It has been well known that anti-TNF drugs might increase lymphoma risk in rheumatoid arthritis (RA), where the rate of lymphoma has already been increased. However, unlike RA, an increased rate of lymphoma has not been reported in ankylosing spondylitis (AS). Hereby, we present a case with AS developing Hodgkin's lymphoma (HL) following 6 months of etanercept treatment. Pathological analysis revealed mixed cellular type of HL. Although we report a single case, it should be kept in mind that anti-TNF drugs might cause lymphoma development not only in RA, but also in AS.
Aksu
Kenan
K
Internal Medicine-Rheumatology Division, Ege University School of Medicine Hospital, Izmir, Turkey. kenan.aksu@ege.edu.tr
Donmez
Ayhan
A
Ertan
Yesim
Y
Keser
Gokhan
G
Inal
Vedat
V
Oder
Gonca
G
Tombuloglu
Murat
M
Kabasakal
Yasemin
Y
Doganavsargil
Eker
E
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept